Related Experiment Videos
Haemophilia prophylaxis in Sweden
Insights
Prophylactic infusions of antihaemophilic factor (AHF) concentrate transformed severe hemophilia A into a moderate form in boys, significantly reducing bleeding episodes and hospitalizations. This treatment allowed children to lead nearly normal lives with fewer joint complications.
Area of Science:
- Hematology
- Pediatric Medicine
- Pharmacology
Background:
- Severe hemophilia A poses significant risks of bleeding and joint damage in children.
- Current treatments often focus on managing acute bleeding events rather than prevention.
- Preventing arthropathy and severe bleeding is crucial for improving long-term quality of life.
Purpose of the Study:
- To evaluate the efficacy of prophylactic antihaemophilic factor (AHF) concentrate infusions in converting severe hemophilia A to a moderate form.
- To assess the impact of this prophylactic regimen on preventing arthropathy and severe bleeding episodes.
- To determine the optimal dosing and interval for AHF concentrate administration through survival studies.
Main Methods:
- 29 boys aged 4-18 with severe hemophilia A received AHF concentrate prophylaxis for 2-13 years.
- Dosing and intervals were adjusted based on AHF survival studies, aiming for 30-45% AHF levels at 5-12 day intervals.
- Patient outcomes, including bleeding frequency/severity, joint health, and hospitalizations, were monitored.
Main Results:
- Prophylaxis successfully reduced hemophilia A from severe to moderate in most patients.
- Bleeding episodes became less frequent and less severe, enabling a near-normal life for the children.
- Hospital stays were significantly reduced; joint function in previously unaffected patients remained comparable to moderate hemophilia.
- Two patients developed inhibitors (anticoagulants), with no other adverse effects reported.
Conclusions:
- Prophylactic AHF concentrate infusions are effective in mitigating the severity of hemophilia A in children.
- This regimen significantly improves quality of life by reducing bleeding complications and joint damage.
- The Swedish prophylactic regimen demonstrates a successful strategy for managing severe hemophilia A.
Abstract:
29 boys (4-18 years old) with severe haemophilia A were given prophylactic infusions of AHF concentrate (human fraction I-0) for 2 to 13 years in an attempt to change the haemophilia from a severe to a moderate form and thereby prevent arthropathy and severe bleeding episodes. The sizes of the doses and the intervals at which the doses were given were titrated by AHF survival studies. As a rule, the patients received AHF in amounts sufficient to raise the AHF level to 30-45% at 5-12 day intervals. In about 50% of the infusions the AHF content was not below 1% before the next infusion. During such prophylaxis all patients except one have been in a good general condition. They have had bleeding episodes, which have, however, been much less severe and less frequent. The children have been able to live an almost normal life. The number and duration of stays in hospital have been markedly reduced. 17 of the patients had only minor or no joint defects before the start of the treatment. In this group the joint function was identical with that found in moderate haemophilia in the same age groups. Two patients developed anticoagulants. No other side effects were seen. The prophylactic regimen in Sweden thus reduced severe haemophilia to moderate.